Sentences with phrase «by breast cancer patients»

This challenge arose from complaints made initially by breast cancer patients who objected to Myriad's monopoly control over the testing and interpretation of risks associated with these cancer genes.

Because of this double effect, it remains unknown whether isoflavone consumption should be encouraged or avoided by breast cancer patients.

Not exact matches

Tears for Life, a team developing a breast cancer tear kit that analyzes a patient's tears, came in second; followed by neoPlastics, a plastic recycling technology firm; and Tetra One Source, which has patented a process for reducing soil toxicity.

A breast cancer advocate honors his mother and other breast cancer patients by sharing the story that set him on an unexpected mission of support.

Advocacy A breast cancer advocate honors his mother and other breast cancer patients by sharing the story that set him on an unexpected mission of support.

American Cancer Society: 800-227-2345 or www.cancer.org Not Just a Patient (contact by email): [email protected] or www.notjustapatient.com Cancer Patient Support Program: 802-847-4848 or 800-358-1144 ext. 4848 or www.cpspvt.org Road to Recovery (transportation to cancer treatment and home again): 802-229-6289 or 800 - ACS - 2345 Women with Cancer — Look Good, Feel Better: 802-229-0366 or 800 - ACS - 2345 Man to Man — Prostate Cancer Education: 802-223-2933 or 802-461-6222 Reach to Recover — Breast Cancer Support: 802-872-6308 or 800 - ACS - 2345 I Can Cope: 802-223-6196, 802-223-7342, 802-225-5400 or 800 - ACS - 2345 Cancer Healing (variety of cancer support groups): 802-229-2234 Cancer Support Potluck: 802-229-5931 Caregivers: 802-223-1878 Energy Healing: 802-223-6043 Christian Mediation: 802-223-6043 Adaptive, Gentle Yoga: 802-229-1134 Look Good... Feel Better: 802-229-0366 Kindred Connections: 800-65Cancer Society: 800-227-2345 or www.cancer.org Not Just a Patient (contact by email): [email protected] or www.notjustapatient.com Cancer Patient Support Program: 802-847-4848 or 800-358-1144 ext. 4848 or www.cpspvt.org Road to Recovery (transportation to cancer treatment and home again): 802-229-6289 or 800 - ACS - 2345 Women with Cancer — Look Good, Feel Better: 802-229-0366 or 800 - ACS - 2345 Man to Man — Prostate Cancer Education: 802-223-2933 or 802-461-6222 Reach to Recover — Breast Cancer Support: 802-872-6308 or 800 - ACS - 2345 I Can Cope: 802-223-6196, 802-223-7342, 802-225-5400 or 800 - ACS - 2345 Cancer Healing (variety of cancer support groups): 802-229-2234 Cancer Support Potluck: 802-229-5931 Caregivers: 802-223-1878 Energy Healing: 802-223-6043 Christian Mediation: 802-223-6043 Adaptive, Gentle Yoga: 802-229-1134 Look Good... Feel Better: 802-229-0366 Kindred Connections: 800-65cancer.org Not Just a Patient (contact by email): [email protected] or www.notjustapatient.com Cancer Patient Support Program: 802-847-4848 or 800-358-1144 ext. 4848 or www.cpspvt.org Road to Recovery (transportation to cancer treatment and home again): 802-229-6289 or 800 - ACS - 2345 Women with Cancer — Look Good, Feel Better: 802-229-0366 or 800 - ACS - 2345 Man to Man — Prostate Cancer Education: 802-223-2933 or 802-461-6222 Reach to Recover — Breast Cancer Support: 802-872-6308 or 800 - ACS - 2345 I Can Cope: 802-223-6196, 802-223-7342, 802-225-5400 or 800 - ACS - 2345 Cancer Healing (variety of cancer support groups): 802-229-2234 Cancer Support Potluck: 802-229-5931 Caregivers: 802-223-1878 Energy Healing: 802-223-6043 Christian Mediation: 802-223-6043 Adaptive, Gentle Yoga: 802-229-1134 Look Good... Feel Better: 802-229-0366 Kindred Connections: 800-65Cancer Patient Support Program: 802-847-4848 or 800-358-1144 ext. 4848 or www.cpspvt.org Road to Recovery (transportation to cancer treatment and home again): 802-229-6289 or 800 - ACS - 2345 Women with Cancer — Look Good, Feel Better: 802-229-0366 or 800 - ACS - 2345 Man to Man — Prostate Cancer Education: 802-223-2933 or 802-461-6222 Reach to Recover — Breast Cancer Support: 802-872-6308 or 800 - ACS - 2345 I Can Cope: 802-223-6196, 802-223-7342, 802-225-5400 or 800 - ACS - 2345 Cancer Healing (variety of cancer support groups): 802-229-2234 Cancer Support Potluck: 802-229-5931 Caregivers: 802-223-1878 Energy Healing: 802-223-6043 Christian Mediation: 802-223-6043 Adaptive, Gentle Yoga: 802-229-1134 Look Good... Feel Better: 802-229-0366 Kindred Connections: 800-65cancer treatment and home again): 802-229-6289 or 800 - ACS - 2345 Women with Cancer — Look Good, Feel Better: 802-229-0366 or 800 - ACS - 2345 Man to Man — Prostate Cancer Education: 802-223-2933 or 802-461-6222 Reach to Recover — Breast Cancer Support: 802-872-6308 or 800 - ACS - 2345 I Can Cope: 802-223-6196, 802-223-7342, 802-225-5400 or 800 - ACS - 2345 Cancer Healing (variety of cancer support groups): 802-229-2234 Cancer Support Potluck: 802-229-5931 Caregivers: 802-223-1878 Energy Healing: 802-223-6043 Christian Mediation: 802-223-6043 Adaptive, Gentle Yoga: 802-229-1134 Look Good... Feel Better: 802-229-0366 Kindred Connections: 800-65Cancer — Look Good, Feel Better: 802-229-0366 or 800 - ACS - 2345 Man to Man — Prostate Cancer Education: 802-223-2933 or 802-461-6222 Reach to Recover — Breast Cancer Support: 802-872-6308 or 800 - ACS - 2345 I Can Cope: 802-223-6196, 802-223-7342, 802-225-5400 or 800 - ACS - 2345 Cancer Healing (variety of cancer support groups): 802-229-2234 Cancer Support Potluck: 802-229-5931 Caregivers: 802-223-1878 Energy Healing: 802-223-6043 Christian Mediation: 802-223-6043 Adaptive, Gentle Yoga: 802-229-1134 Look Good... Feel Better: 802-229-0366 Kindred Connections: 800-65Cancer Education: 802-223-2933 or 802-461-6222 Reach to Recover — Breast Cancer Support: 802-872-6308 or 800 - ACS - 2345 I Can Cope: 802-223-6196, 802-223-7342, 802-225-5400 or 800 - ACS - 2345 Cancer Healing (variety of cancer support groups): 802-229-2234 Cancer Support Potluck: 802-229-5931 Caregivers: 802-223-1878 Energy Healing: 802-223-6043 Christian Mediation: 802-223-6043 Adaptive, Gentle Yoga: 802-229-1134 Look Good... Feel Better: 802-229-0366 Kindred Connections: 800-65Cancer Support: 802-872-6308 or 800 - ACS - 2345 I Can Cope: 802-223-6196, 802-223-7342, 802-225-5400 or 800 - ACS - 2345 Cancer Healing (variety of cancer support groups): 802-229-2234 Cancer Support Potluck: 802-229-5931 Caregivers: 802-223-1878 Energy Healing: 802-223-6043 Christian Mediation: 802-223-6043 Adaptive, Gentle Yoga: 802-229-1134 Look Good... Feel Better: 802-229-0366 Kindred Connections: 800-65Cancer Healing (variety of cancer support groups): 802-229-2234 Cancer Support Potluck: 802-229-5931 Caregivers: 802-223-1878 Energy Healing: 802-223-6043 Christian Mediation: 802-223-6043 Adaptive, Gentle Yoga: 802-229-1134 Look Good... Feel Better: 802-229-0366 Kindred Connections: 800-65cancer support groups): 802-229-2234 Cancer Support Potluck: 802-229-5931 Caregivers: 802-223-1878 Energy Healing: 802-223-6043 Christian Mediation: 802-223-6043 Adaptive, Gentle Yoga: 802-229-1134 Look Good... Feel Better: 802-229-0366 Kindred Connections: 800-65Cancer Support Potluck: 802-229-5931 Caregivers: 802-223-1878 Energy Healing: 802-223-6043 Christian Mediation: 802-223-6043 Adaptive, Gentle Yoga: 802-229-1134 Look Good... Feel Better: 802-229-0366 Kindred Connections: 800-652-5064

Statement from Breast Cancer Care on research presented by Heemskerk - Gerritsen and Pierce at the seventh European Breast Cancer Conference on surgical options for patients with inherited breast cBreast Cancer Care on research presented by Heemskerk - Gerritsen and Pierce at the seventh European Breast Cancer Conference on surgical options for patients with inherited breast cCancer Care on research presented by Heemskerk - Gerritsen and Pierce at the seventh European Breast Cancer Conference on surgical options for patients with inherited breast cBreast Cancer Conference on surgical options for patients with inherited breast cCancer Conference on surgical options for patients with inherited breast cbreast cancercancer.

Two week wait — 96.2 % of patients were seen by a specialist within two weeks of an urgent GP referral for suspected cancer --(95.7 % in Q2 2011 - 12) Breast symptom two week wait — 96.3 % of people urgently referred for breast symptoms (where cancer was not initially suspected) were seen within two weeks of referral (96.0 % in Q2 2011Breast symptom two week wait — 96.3 % of people urgently referred for breast symptoms (where cancer was not initially suspected) were seen within two weeks of referral (96.0 % in Q2 2011breast symptoms (where cancer was not initially suspected) were seen within two weeks of referral (96.0 % in Q2 2011 - 12)

This may be explained by delays in diagnosis and the «under - treatment» of older breast cancer patients.

The findings, presented at the 2016 San Antonio Breast Cancer Symposium in a poster session by Cameron W. Swanick, M.D., should serve as an important discussion point between older patients and their physicians when making treatment decisions.

«If we know which genes are damaged in a breast cancer patient's immune system, prevention or even therapy can be tailored by giving vaccines or perhaps antiviral drugs to reduce the chances of recurrence,» said Friedenson.

Vitamin C has previously been shown to be effective as a non-toxic anti-cancer agent in studies by Nobel Prize winner Linus Pauling and was recently shown to reduce mortality by 25 % on breast cancer patients in Japan.

Ziskin, a Hollywood film producer who died of metastatic breast cancer, was a co-founder of Stand Up To Cancer, an initiative founded in 2008 by nine women in the entertainment industry to accelerate groundbreaking research and bring new treatments to patients as quickly as poscancer, was a co-founder of Stand Up To Cancer, an initiative founded in 2008 by nine women in the entertainment industry to accelerate groundbreaking research and bring new treatments to patients as quickly as posCancer, an initiative founded in 2008 by nine women in the entertainment industry to accelerate groundbreaking research and bring new treatments to patients as quickly as possible.

The study, «AKR1B1 promotes basal - like breast cancer progression by a positive feedback loop that activates the EMT program,» which has been published in The Journal of Experimental Medicine, suggests that an inhibitor of this enzyme currently used to treat diabetes patients could be an effective therapy for this frequently deadly form of cancer.

Another study, conducted by Barbara Weber and her colleagues at the University of Pennsylvania, screened 263 breast cancer patients for BRCA1 mutations and asked them about their family history of breast and ovarian cancers.

Stamets furnished capsules of freeze - dried fungus for a seven - year, NIH - funded study by Bastyr University and the University of Minnesota to determine whether turkey tail mushrooms could help breast cancer patients whose immune systems had been compromised by radiation therapy.

The highest prevalence was found among patients with breast cancer (42 %) and head and neck cancer (41 %), followed by malignant melanoma (39 %).

«We hope that our test will significantly improve the odds of survival of breast cancer patients by allowing doctors to identify the most effective but least toxic form of chemotherapy for each individual patient before the treatment begins.»

Using data from a previously published, multi-center study funded by the National Cancer Institute, researchers aimed to identify the possible benefits of assigning patient navigators to women recently diagnosed with breast cCancer Institute, researchers aimed to identify the possible benefits of assigning patient navigators to women recently diagnosed with breast cancercancer.

Despite the extensive screening programme, a large proportion of all breast cancer cases are detected by the patient herself.

«Our data confirmed that, while the rate of growth of triple - negative breast cancer was not affected by CDK 4/6 inhibitors, this class of drugs was able to significantly inhibit the spread of triple - negative breast cancer to distant organs when tested in multiple different triple - negative breast cancer models, including patient - derived xenografts.»

«Improving breast cancer chemo by testing patient's tumors in a dish.»

The time needed for breast cancer metastases (secondary lesions caused by cells that have escaped from the original tumour) to develop varies between patients, and little is known about the mechanisms that govern latency (the dormant state of cells that have already spread through the body).

The immunotherapy drug pembrolizumab — already FDA - approved for other forms of cancer - has been found to be effective in patients with metastatic triple negative breast cancer, according to an international clinical trial led by NYU Langone's Perlmutter Cancer Ccancer - has been found to be effective in patients with metastatic triple negative breast cancer, according to an international clinical trial led by NYU Langone's Perlmutter Cancer Ccancer, according to an international clinical trial led by NYU Langone's Perlmutter Cancer CCancer Center.

Kontos adds that a greater role for aspirin would be welcomed by many at - risk patients, as current drugs aimed at reducing risk, such as tamoxifen and raloxifene, have significant side effects and do not prevent ER - negative breast cancer.

The study, which will be published December 21 in the Journal of Cell Biology, suggests that the loss of these particular Numb proteins makes breast cancers more aggressive and resistant to chemotherapy, but points the way toward new therapeutic approaches that could improve patient outcome by preserving p53 levels.

«By accurately assessing tumor resection margins intraoperatively with CLI, surgeons may be able to completely clear the cancer with a single operation, thereby reducing the number of breast cancer patients requiring a second, or even third, surgical procedure.

Should the results be confirmed by further studies, it is possible that patients with certain genetic changes in BRCA1 could be identified as being at higher risk of breast and ovarian cancer.

By examining patient tissue samples and information about whether each person had had a recurrence, the scientists discovered that high FAK activity was linked to the disease returning, either as DCIS or invasive breast cancer.

By performing a genome - wide screen in breast cancer cells, Dr. Oesterreich and her colleagues identified a gene called HOXC10 as one that the cancer seems to modify to allow continued tumor growth in patients whose cancer becomes resistant to traditional therapies.

A breast cancer therapy that blocks estrogen synthesis to activate cancer - killing genes sometimes loses its effectiveness because the cancer takes over epigenetic mechanisms, including permanent DNA modifications in the patient's tumor, once again allowing tumor growth, according to an international team headed by the University of Pittsburgh Cancer Institute (cancer therapy that blocks estrogen synthesis to activate cancer - killing genes sometimes loses its effectiveness because the cancer takes over epigenetic mechanisms, including permanent DNA modifications in the patient's tumor, once again allowing tumor growth, according to an international team headed by the University of Pittsburgh Cancer Institute (cancer - killing genes sometimes loses its effectiveness because the cancer takes over epigenetic mechanisms, including permanent DNA modifications in the patient's tumor, once again allowing tumor growth, according to an international team headed by the University of Pittsburgh Cancer Institute (cancer takes over epigenetic mechanisms, including permanent DNA modifications in the patient's tumor, once again allowing tumor growth, according to an international team headed by the University of Pittsburgh Cancer Institute (Cancer Institute (UPCI).

A study done by researchers at Fox Chase Cancer Center shows that many relatives of patients who undergo testing for a gene linked to breast and ovarian cancers misinterpret the results, and less than half of those who could benefit from genetic testing say they plan to get tested themselves — despite the fact that knowing your genetic status may help catch the disease in its earliest stages.

«It's incredibly encouraging to find possible new options for patients with an aggressive cancer like triple negative breast cancer, and that studies conducted by separate teams at leading institutions agree on the implications of the findings,» said Alan Ashworth, PhD, FRS, president of UCSF Helen Diller Family Comprehensive Cancer Center, and former CEO of thcancer like triple negative breast cancer, and that studies conducted by separate teams at leading institutions agree on the implications of the findings,» said Alan Ashworth, PhD, FRS, president of UCSF Helen Diller Family Comprehensive Cancer Center, and former CEO of thcancer, and that studies conducted by separate teams at leading institutions agree on the implications of the findings,» said Alan Ashworth, PhD, FRS, president of UCSF Helen Diller Family Comprehensive Cancer Center, and former CEO of thCancer Center, and former CEO of the ICR.

Many breast cancers are marked by a lack of HOXA5 protein, a gene product known to control cell differentiation and death, and lower levels of the protein correspond to poorer outcomes for patients.

The findings could lead to future investigation into potential new ways to treat and monitor breast cancer by looking outside the tumor and exploiting the patient's systemic immune system response.

The researchers, including scientists from The Genome Institute at Washington University School of Medicine, presented the research titled, «Patient - derived xenograft study reveals endocrine therapy resistance of ER + breast cancer caused by distinct ESR1 gene aberrations.»

Hormonal therapy for patients with estrogen - or progesterone - positive breast cancers can reduce the risk of cancer recurrence by as much as 50 percent.

An international collaboration, led by the Wellcome Trust Sanger Institute with contributions from the European Bioinformatics Institute (EMBL - EBI), analysed 560 breast cancer genomes from cancer patients from the US, Europe and Asia.

Adding this variable angle slant hole collimator to an existing breast molecular imaging system allows the system to get six times better contrast of cancer lesions in the breast, providing the same or better image quality while also potentially reducing the radiation dose to the patient by half.

The researchers found that over 25 percent of index patients with normal results from commercial testing of BRCA1 and BRCA2, but with families severely affected by breast cancer, could be resolved by sequencing all genes known to be involved in breast cancer.

Affecting about one breast cancer patient in four, it is characterized by tumor cells overexpressing a signaling protein called HER2.

The commercial testing occurred because the patients had a severe family history of breast cancer, defined as a family with three or more relatives affected by breast or ovarian cancer.

The highest suicide risk was observed in lung cancer patients (SMR = 4.2) followed by CRC (SMR = 1.4), breast cancer (SMR = 1.4) and prostate cancer (SMR = 1.2).

Previous in vitro studies conducted by researchers in other countries showed that this molecule was able to reduce the multiplication and increase the mortality of cells from melanoma, the most aggressive type of skin cancer, as well as breast cancer and neuroblastoma, a tumor that typically affects patients aged 15 or younger.

Their findings could help to improve breast cancer prevention by targeting these specific biological mechanisms with cancer therapies in at risk patients and potentially lead the way for a new strategy for the use of preventative treatments.

The U.S. Food and Drug Administration (FDA) in 2004 approved the CellSearch system, made by Johnson & Johnson's Veridex unit, for identifying and counting CTCs in patients with metastatic breast cancer.

Based on these results, two phase 3 trials are being planned for platinum - sensitive and platinum - resistant ovarian cancer patients by one of NCI's new National Cancer Trial Network Groups, the NRG Oncology Group (formerly 3 cooperative groups: the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group cancer patients by one of NCI's new National Cancer Trial Network Groups, the NRG Oncology Group (formerly 3 cooperative groups: the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group Cancer Trial Network Groups, the NRG Oncology Group (formerly 3 cooperative groups: the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group (GOG).

In the case of breast cancer driven by overexpression of the HER2 gene, up to 50 percent of patients treated with targeted therapies eventually develop brain metastases, which are inevitably fatal.

Chair of EBCC10, Professor Fatima Cardoso, who is Director of the Breast Unit at the Champalimaud Clinical Centre, Lisbon, Portugal, said: «This study suggests that the worse prognosis seen in breast cancer patients from ethnic minority groups in the UK can be at least in part explained by the younger age of this Breast Unit at the Champalimaud Clinical Centre, Lisbon, Portugal, said: «This study suggests that the worse prognosis seen in breast cancer patients from ethnic minority groups in the UK can be at least in part explained by the younger age of this breast cancer patients from ethnic minority groups in the UK can be at least in part explained by the younger age of this group.

The identification of patients with high - risk breast cancer is key to knowing whether a patient will require only the removal of the tumor by surgery or whether if she will need additional chemotherapy to make sure the removal of breast cancer cells.